The global painkillers market is expected to enjoy a valuation of USD 70.0 Billion by the end of the year 2023, and further expand at a CAGR of 3.7% to reach a valuation of ~USD 100.9 Billion by the year 2033. According to a recent study by Future Market Insights, opioids are leading the market with a share of about 53.4% in the year 2022, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 67.7 Billion |
| Market Value 2023 | USD 70.0 Billion |
| Market Value 2033 | USD 100.9 Billion |
| CAGR 2023 to 2032 | 3.7% |
| Market Share of Top 5 Countries (2022) | 59.1% |
| Key Market Players | AbbVie Inc. (Allergan plc), Bristol Myers Squibb Co., Sanofi S.A., Boehringer Ingelheim International GmbH, Pfizer Inc., Zydus Lifesciences Ltd. (Cadila Pharmaceuticals), GSK plc., Abbott Laboratories, Inc., Novartis AG, Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Procter & Gamble, AstraZeneca, Cardinal Health, Perrigo Company Plc., Bausch Health Companies Inc., Viatris, Amneal Pharmaceuticals, and Purdue Pharmaceuticals L.P. |
Manufacturers are focused on developing non-opioid drugs with a novel extended-release delivery approach that can relieve postoperative pain over a longer period of time. Opioid drugs are highly effective pain relievers, but they are also highly addictive and can lead to abuse and dependence. The opioid epidemic has led to a growing need for non-opioid pain management options.
Overall, the development of non-opioid extended-release pain medications is an important step in addressing the opioid epidemic and providing patients with a safer option, thereby will drive the overall growth of the painkillers market during the forecast period (2023 to 2033).
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The market value for painkillers was around 4.8% of the overall ~USD 1,400.5 Billion of the global pharmaceuticals market in 2022.
An increasing number of patients suffering from chronic diseases such as cancer and chronic obstructive pulmonary disease (COPD), various prescription drugs for postoperative pain management, and various traumas leading to pain are expected to fuel the growth of global market for painkillers.
Certain health conditions such as diabetes, cancer, and autoimmune diseases are known to increase the risk of developing chronic pain and neuropathic pain. Therefore, it is important that healthcare providers are aware of the increasing prevalence of these conditions and provide appropriate treatment strategies to improve patients’ quality of life.
Overall, the global market is projected to expand at a CAGR of 3.7% during the forecast period (2023 to 2033).
The regulatory scenario for painkillers can have a significant impact on the growth of the market. In recent years, opioid pain medications have come under increased scrutiny, resulting in stricter regulations and restrictions on their use. This has created opportunities for non-opioid pain medications such as NSAIDs and other non-narcotic medications to gain market share. In addition, regulatory initiatives to improve pain management and reduce opioid abuse, such as prescription drug monitoring programs and physician education programs, may create opportunities for companies offering alternative pain management solutions.
Overall, the regulatory scenario for painkillers is complex and evolving. However, regulatory initiatives that promote safe and effective pain management can create growth opportunities for the painkillers manufacturers, especially for companies that offer innovative solutions.
The companies that navigate the regulatory landscape and invest in innovative solutions to meet the evolving needs of patients and healthcare providers offer lucrative growth opportunities for the market and will raise the market to new heights during the forecast period from 2023 to 2033.
Per capita use of opioids is low in Asian countries. According to the Global Opioids Policy Initiative (GOPI), some of the main factors responsible for low opioid use in Asia and Africa include: full patient cost coverage is required, patient registration required before prescribing opioids, and physicians must obtain special permission to prescribe opioids.
The availability of painkillers in Asian and African countries may have a significant impact on the growth of the painkiller market in these regions. In many of these countries, access to painkillers is limited due to various factors such as lack of infrastructure, regulatory issues, and economic constraints. This can lead to a significant unmet need for painkillers, which can ultimately impact the growth of the market.
These factors are negatively impacting the growth of the painkillers market in Asia and Africa and projections have been made which are restraining the growth of the market during the forecast period from 2023 to 2033 in the world.
With a market share of 91.5% in 2022, the USA will continue to dominate the North American region. This large market share is expected to continue throughout the forecast period.
In the USA, palliative care facilities are provided in accordance with government and commercial reimbursement guidelines. Palliative care programs in hospitals in the USA include dedicated inpatient palliative care units and palliative care consultation teams.
Also, the American Chronic Pain Association has designated September as Pain Awareness Month, and more than 80 organizations and healthcare professionals, and consumer groups have supported the initiative. This will result in the propulsion of demand for painkillers in the country during the forecast period of 2023 to 2033.
Germany dominates the Western European region with a total market share of about 25.6% in 2022 and is expected to continue to experience the same growth throughout the forecast period.
In Germany, there is a growing interest in personalized medicine, which is also reflected in the painkillers market. Pharmaceutical companies are developing painkillers tailored to specific patient groups, such as the elderly or people with kidney problems, in order to achieve more targeted and effective pain relief. This will foster profitable market growth over the course of the forecast period.
Japan dominates the East Asia region with market share of 45.1% in 2022 and will expand with growing numbers in the future.
Japan has taken various initiatives to improve pain management, including the establishment of pain clinics, the development of clinical guidelines for pain management, and the training of healthcare professionals in pain management.
The Japan market for painkillers is expected to continue to grow in the coming years, driven by changing demographics, shifting consumer preferences, and increasing investment in pain management R&D all suggest that Japan will continue to be an important market for painkillers.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Opioids are expected to present growth at a CAGR of 2.1% throughout the forecast period, with a market share of 53.4% in the global market in 2022.
Opioids are relatively inexpensive compared to some of the newer non-opioid pain medications. Opioids have been used for pain relief for centuries, and many healthcare providers are familiar with their use and feel comfortable prescribing them.
As the demand for non-opioids continues to grow, the market for painkillers is expected to expand significantly in the coming years.
Prescription Drugs dominated the global market with a value share of 58.8% in 2022.
Prescription drugs are leading in the global market for painkillers over over-the-counter (OTC) drugs because they are often more effective at providing pain relief for moderate to severe pain. Prescription painkillers are also often covered by health insurance, which can make them more affordable for patients who need them.
Surgical pain is leading the market with a market share of 43.3% in the global market in 2022.
Surgical pain is leading in the market over other indications because surgery is a common cause of acute pain, and pain relief is an important part of the post-surgical recovery process. Many surgical procedures can be painful, and without adequate pain control, patients may experience significant discomfort, which can delay healing and recovery.
The oral route of administration is leading the market with a revenue share of 38.7% in 2022 as oral painkillers are easy to take and can be self-administered, which can make them more convenient for patients and also it is generally less invasive than other routes, such as injections or transdermal patches, which can make it more appealing for patients.
Retail pharmacies hold a market share value of 27.5% during the year 2022. Retail pharmacies typically stock a wide range of painkillers, including both prescription and over-the-counter options and they are easily accessible to consumers, which makes it convenient for them to purchase painkillers.
Key market players in the painkillers market launch their products. This promotional strategy is expected to be highly impactful to enter into the market.
A few of the recent instances include
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the Painkillers market, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2018 to 2022 |
| Historical Data Available for | 2023 to 2032 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Western Europe; Eastern Europe; Russia & Belarus; Balkan & Baltic Countries; South Asia & Pacific; East Asia; Central Asia; and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, Spain, France, BENELUX, Nordic Countries, Poland, Hungary, Czech Republic, Romania, Russia and Belarus, Balkan & Baltic Countries, India, Thailand, Indonesia, Malaysia, Vietnam, Philippines, Japan, China, South Korea, Central Asia, Australia and New Zealand, Türkiye, GCC Countries, Kingdom of Saudi Arabia, Israel, North Africa, and South Africa |
| Key Market Segments Covered | Drug Class, Product, Indication, Route of Administration, Distribution Channel, and Region |
| Key Companies Profiled | AbbVie Inc. (Allergan plc); Bristol Myers Squibb Co.; Sanofi S.A.; Boehringer Ingelheim International GmbH; Pfizer Inc.; Zydus Lifesciences Ltd. (Cadila Pharmaceuticals); GSK plc.; Abbott Laboratories, Inc.; Novartis AG; Johnson & Johnson (Janssen Pharmaceuticals, Inc.); Sun Pharmaceutical Industries Ltd.; Teva Pharmaceuticals Ltd.; Mallinckrodt Pharmaceuticals; Endo Pharmaceuticals Inc.; Bayer AG; F. Hoffmann-La Roche Ltd.; Procter & Gamble; AstraZeneca; Cardinal Health; Perrigo Company Plc.; Bausch Health Companies Inc.; Viatris; Amneal Pharmaceuticals; Purdue Pharmaceuticals L.P. |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The painkillers market is expected to reach a valuation of at USD 70.0 billion in 2023.
AbbVie Inc. (Allergan plc), Bristol Myers Squibb Co., Sanofi S.A., are leading painkillers industry players.
Opioids are the key segment by drug class in the worldwide painkillers market.
Over the historical period, from 2018 to 2022, the painkillers market registered a 2.9% CAGR.
North America painkillers market is expected to hold a 92.2% share in 2023.
| Estimated Size, 2024 | USD 50,611.1 million |
|---|---|
| Projected Size, 2034 | USD 74,757.4 million |
| Value-based CAGR (2024 to 2034) | 4.0% |
| Market Value for 2024 | USD 23,705.60 million |
|---|---|
| Market Value for 2034 | USD 35,090.10 million |
| Market CAGR (2024 to 2034) | 4.0% |
| Expected Market Value (2023) | USD 60 Billion |
|---|---|
| Anticipated Forecast Value (2033) | USD 100 Billion |
| Projected Growth Rate (2023 to 2033) | 5% CAGR |
| Market Size (2023) | USD 38.43 billion |
|---|---|
| Market Value (2033) | USD 63.8 billion |
| CAGR (2023 to 2033) | 5.2% |
Explore Therapy Area Insights
View Reports
Painkillers Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
